Acute Ischemic Stroke companies working in the treatment market are Acticor Biotech, Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others, are developing therapies for ...

Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...

Q2 2025 Earnings Call Transcript August 6, 2025 Fortrea Holdings Inc. beats earnings expectations. Reported EPS is $0.19, ...

DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which ...

Objectives Athletes have been found to experience a similar prevalence of mental health issues to non-athletes. However, they are subjected to a greater array of barriers to help-seeking for mental ...

Researchers at Harvard Medical School have identified a potential breakthrough in understanding Alzheimer's disease after ...

The "Pneumococcal Disease - Pipeline Insight, 2025" report offers in-depth analysis of over 20 drugs and 18 companies in the Pneumococcal Disease pipeline, covering clinical and nonclinical stages.

Research and development expenses grew 16.7% year-over-year in Q2 2025, while net loss (GAAP) widened to $26.8 million. No revenue was reported, and Immunic requires additional funding within twelve ...